TScan Therapeutics inks $100m Series C

TScan Therapeutics, a developer of T-cell receptor engineered T cell therapies in oncology, has raised $100 million in Series C financing.

TScan Therapeutics, a developer of T-cell receptor engineered T cell therapies in oncology, has raised $100 million in Series C financing. The investors included BlackRock, RA Capital Management, Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech.

Source: Press Release